Description:
IC50 Value: N/A
RGFP 109 is a histone deacetylase inhibitor which can attenuate L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset.
in vitro: N/A
in vivo: RGFP109 had no acute effects on dyskinesia after single or 6 days once-daily treatment (both P > 0.05). However, one week following cessation of RGFP109, dyskinesia and duration of ON-time with disabling dyskinesia were reduced by 37% and 50%, respectively (both P < 0.05), compared to that seen previously with L-DOPA alone. There was no change in anti-parkinsonian actions of, or ON-time duration afforded by, L-DOPA (P > 0.05) [1].
Clinical trial: Phase 1